Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
- Conditions
- Amyotrophic Lateral Sclerosis
- Registration Number
- NCT00596115
- Lead Sponsor
- Bennett, James P., Jr., M.D., Ph.D.
- Brief Summary
R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TEMPORARILY_NOT_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Definite diagnosis of ALS
Exclusion Criteria
- No prior participation in R(+)PPX clinical studies
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method